Overview

A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection

Status:
Completed

Trial end date:
2017-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to compare the safety and efficacy of ABT-493/ABT-530 to the combination of sofosbuvir (SOF) and daclatasvir (DCV) in adults with genotype 3 (GT3) chronic hepatitis C virus (HCV) infection.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Sofosbuvir